This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61K 31/5415, 31/473, 31/496, 31/517, A61P 35/00, G01N 33/50

(11) International Publication Number:

WO 00/32175

A3 |

(43) International Publication Date:

8 June 2000 (08.06.00)

(21) International Application Number:

PCT/IB99/01916

(22) International Filing Date:

1 December 1999 (01.12.99)

(30) Priority Data:

60/110,542

- 2 December 1998 (02.12.98) US
- (71) Applicant: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).
- (72) Inventors: COFFEY, Heather, Anne; Pfizer Inc., Central Research Division, Eastern Point Road, Groton, CT 06340 (US). CONNELL, Richard, Damian; Pfizer Inc., Central Research Division, Eastern Point Road, Groton, CT 06340 (US). FOSTER, Barbara, Ann; Pfizer Inc., Central Research Division, Eastern Point Road, Groton, CT 06340 (US). RASTINEJAD, Farzan; Pfizer Inc., Central Research Division, Eastern Point Road, Groton, CT 06340 (US).
- (74) Agents: SPIEGEL, Allen, J. et al.; c/o Simpson, Alison, Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published


With international search report.


Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.


(88) Date of publication of the international search report:


3 August 2000 (03.08.00)


(54) Title: METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY














(57) Abstract

The invention provides pharmaceutical non-peptidic organic compounds capable of interacting with a functionally defective form of a mutant or a wild-type tumor suppressor protein of the p53 family (such as p53, p63 or p73). The interaction allows stabilization or folding of the protein in a functional conformation, thereby restoring all or part of its wild-type normal activity. More particularly said compounds interact with the DNA binding domain of p53 family proteins, are acridine, quinoline, quinazoline or phenothiazine derivatives, and are used in cancer therapy. Also provided are methods for screening such pharmacological compounds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	. MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ.	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Кепуа	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	Lľ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Jonal Application No PCT/IB 99/01916

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/5415 A61K31/473 A61K31/496 A61K31/517 A61P35/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC $\,7\,$ A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Υ	HAINAUT ET AL.: "Redox modulation of p53 conformation and sequence DNA-binding in-vitro" CANCER RESEARCH, vol. 35, no. 18, 1 October 1993 (1993-10-01), pages 4469-4473, XP000891856 the whole document	1-3,5	
Y	WO 94 12202 A (UNIVERSITY OF DUNDEE) 9 June 1994 (1994-06-09) see claims	1-3,5, 9-11,22, 23 6,12,13,	
	page 32 -page 33, paragraph 1 see pages 7,8.12-16, 29 and 30 abstract	16-19	

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents: A* document defining the general state of the art which is not considered to be of particular relevance E* earlier document but published on or after the international filing date L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O* document referring to an oral disclosure, use, exhibition or other means P* document published prior to the international filing date but later than the priority date claimed	T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention invention. "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone. "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents acombination being obvious to a person addited in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
29 May 2000	07/06/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijawijk	Authorized officer
Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Gac, G

5

In. Honal Application No PCT/IB 99/01916

		FC1/1B 39/01910
C.(Continu	ation) DOCUMENT'S CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RYAN ET AL.: "Alteration of p53 conformation and induction of apoptosis in a murine erythroleukemia cell line by dimethylsulfoxide" LEUKEMIA RESEARCH, vol. 18, no. 8, 1994, pages 617-621, XP000901852 the whole document	1-3,5
Y	BROWN ET AL.: "Chemical chaperones correct the temperature sensitive protein folding defects associated with p53 and ubiquitin" MOL. BIOL. CELL., vol. 7, no. suppl., December 1996 (1996–12), page 337a XP000901864 see abstract 1956	1-3, 9-11,23
A	BROWN ET AL.: "Correcting temperature-sensitive protein folding defects" J. CLIN. INVEST., vol. 99, no. 6, 15 March 1997 (1997-03-15), pages 1432-1444, XP000901689 abstract page 1434 -page 1435 page 1440 -page 1443 figure 4	1-3,5,6, 9-13, 17-19,23
A	WO 97 37645 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 16 October 1997 (1997-10-16) figures 18,19 claims 1,3,5,7 page 25, line 8 - line 11 page 24, line 25 - line 30 page 13, line 19 - line 28 page 10 page 9, line 10 - line 25 page 6, line 18 - line 26 page 5, line 26 - line 27	1-3, 9-11,16
Y	SHEKHAR ET AL.: "Altered p53 conformation: a novel mechanism of wild-type p53 functional inactivation in a model for early breast cancer" INT. J. ONCOL., vol. 11, no. 5, November 1997 (1997-11), pages 1087-1094, XP000901870 the whole document	1-3,22
A		17-19

5

tn Honai Application No PCT/IB 99/01916

		FC1/18 99/01910	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Helevant to claim No.	
A	HAINAUT ET AL.: "A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53" CANCER RESEARCH, vol. 53, no. 8, 1993, pages 1739-1742, XP000891855 the whole document	1-3,5	
A	BLAGOSKLONNY ET AL.: "Geldanamycin selectively destabilizes mutant p53" PROC. ANNU. MEET. AM. ASSOC. CANCER RES., vol. 36, March 1995 (1995-03), page 429 XP000891847 see abstract 2558	1-3, 9-11, 17-19	
A	CHEMICAL ABSTRACTS, vol. 124, no. 25, 17 June 1996 (1996-06-17) Columbus, Ohio, US; abstract no. 332043, SAKAGAMI, KIROSHI ET AL: "Induction of DNA fragmentation in human myelogenous leukemic cell lines by phenothiazine-related compounds" XP000901771 abstract & ANTICANCER RES. (1995), 15(6B), 2533-40 the whole document	17,20	
A	CHEMICAL ABSTRACTS, vol. 128, no. 14, 6 April 1998 (1998-04-06) Columbus, Ohio, US; abstract no. 162631, WUONOLA, MARK A. ET AL: "The primary in vitro antitumor screening of "half-mustard type" phenothiazines" XP000901768 abstract & ANTICANCER RES. (1997), 17(5A), 3409-3423, the whole document	17,20	
A	NAGY ET AL.: "Antitumor activity of phenothiazine-related compounds" CANCER RESEARCH, vol. 16, no. 4a, 1996, pages 1915-1918, XP000901776 the whole document ————————————————————————————————————	17,20	

tr tional Application No PCT/IB 99/01916

	PC1/1B 99/01916
ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
MOTOHASHI ET AL.: "Synthesis and antitumor activity of 1-'2-(chloroethyl)-3-(2-substituted-10H-ph enothiazin-10-yl)ALKYL-1! ureas as potent anticancer agents" ANTICANCER RESEARCH, vol. 16, no. 5a, 1996, pages 2525-2532, XP000901777 the whole document	17,20
GNIAZDOWSKI ET AL.: "Thiol-dependent inhibition of RNA synthesis in-vitro by acridines,. Structure-inhibition relationship" CANCER LETTERS, vol. 15, no. 1, 1982, pages 73-79, XP000901862 the whole document	17,20
WILSON ET AL.: "Hypoxia-selective antituomr agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives" J. MED. CHEM., vol. 32, no. 1, 1989, pages 31-38, XP000891841 see compound 15 page 34	24,25
HUPP ET AL.: "Regulation of p53 protein function through alterations in protein-folding pathways" CELL. MOL. LIFE SCI., vol. 55, no. 1, January 1999 (1999-01), pages 88-95, XP000891820 page 91, right-hand column -page 93, left-hand column	1-3,5,6, 9-13, 16-19, 22,23
OHNISHI ET AL.: "Restoration of mutant TP53 to normal TP53 function by glycerol as a chemical chaperone" RADIATION RES., vol. 151, no. 4, April 1999 (1999-04), pages 498-500, XP000904809 the whole document	1-3,5,6, 9-13, 16-19,23
	MOTOHASHI ET AL.: "Synthesis and antitumor activity of 1-'2-(chloroethyl)-3-(2-substituted-10H-ph enothiazin-10-yl)ALKYL-1! ureas as potent anticancer agents" ANTICANCER RESEARCH, vol. 16, no. 5a, 1996, pages 2525-2532, XP000901777 the whole document GNIAZDOWSKI ET AL.: "Thiol-dependent inhibition of RNA synthesis in-vitro by acridines,. Structure-inhibition relationship" CANCER LETTERS, vol. 15, no. 1, 1982, pages 73-79, XP000901862 the whole document WILSON ET AL.: "Hypoxia-selective antituomr agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives" J. MED. CHEM., vol. 32, no. 1, 1989, pages 31-38, XP000891841 see compound 15 page 34 HUPP ET AL.: "Regulation of p53 protein function through alterations in protein-folding pathways" CELL. MOL. LIFE SCI., vol. 55, no. 1, January 1999 (1999-01), pages 88-95, XP000891820 page 91, right-hand column -page 93, left-hand column OHNISHI ET AL.: "Restoration of mutant TP53 to normal TP53 function by glycerol as a chemical chaperone" RADIATION RES., vol. 151, no. 4, April 1999 (1999-04), pages 498-500, XP000904809

...amational application No.

PCT/IB 99/01916

Box I Ot	bservations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Interna	tional Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
	aims Nos.: cause they relate to subject matter not required to be searched by this Authority, namely:
bed	aims Nos.: cause they relate to parts of the International Application that do not comply with the prescribed requirements to such extent that no meaningful International Search can be carried out, specifically:
3. Cia	aims Nos.: cause they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Ob	oservations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This internal	tional Searching Authority found multiple inventions in this International application, as follows:
1. As see	all required additional search fees were timely paid by the applicant, this international Search Report covers all archable claims.
2. As of a	all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment any additional fee.
3. As cov	only some of the required additional search fees were timely paid by the applicant, this International Search Report rers only those claims for which fees were paid, specifically claims Nos.:
4. No rest	required additional search fees were timely paid by the applicant. Consequently, this international Search Report is tricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on i	Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 4 and 20 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Present claims 1-3,5-15,17-19,21-23 relate to compounds, methods and diseases defined by reference to desirable or undesirable characteristics and properties, namely:

- * compounds by being a "non-peptide compound", being "capable of binding to one or more domains of mutant p53 protein under physiological conditions and of stabilizing a functional conformation therein".

 * methods of "promoting wild-type activity in a mutant form of human protein of the p53 family, wherein one or more functional activities of said protein are at least partially impaired by the inability of said protein to maintain a functional conformation under physiological
- * " a disease state associated with possesssion of a mutant protein of the p53 family having one or more diminished woild-type activities". The claims cover all compounds, methods and diseases having these characteristics and properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compoundshods/apparatus. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds and methods by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds of claims 24 and 25 and on therapy of cancer, with due regard to the general idea underlying the application.

CONCLUSION:

conditions".

- Claims not searched: claims 1-23
- claims searched: claims 24 and 25 as far as relating to the therapy of cancer.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

information on patent family members

In Monal Application No
PCT/IB 99/01916

Patent document cited in search repor	t	Publication date		Patent family member(s)	Publication date
WO 9412202	A	09-06-1994	AT	180673 T	15-06-1999
			AU	680216 B	24-07-1997
			AU	5533194 A	22-06-1994
			CA	2150265 A	09-06-1994
			DE	69325180 D	08-07-1999
			DE	69325180 T	02-12-1999
			EP	0675729 A	11-10-1995
			ËS	2134336 T	01-10-1999
			GR	3030900 T	30-11-1999
			JP	8505607 T	18-06-1996
WO 9737645	A	16-10-1997	AU	2448597 A	29-10-1997
	• • •		CA	2250780 A	16-10-1997
			EP	0959877 A	01-12-1999
			ŪS	5900360 A	04-05-1999